Pascal de Groote
Impact in
-
- Heart Failure Treatment and Management
- Cardiomyopathy and Myosin Studies
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Cardiac Fibrosis and Remodeling
- Cardiac electrophysiology and arrhythmias
- Pulmonary and Respiratory Medicine top 0.5%
- Pulmonary Hypertension Research and Treatments
Papers in
-
- Heart Failure Treatment and Management 55
- Cardiomyopathy and Myosin Studies 19
- Cardiovascular Function and Risk Factors 18
- Cardiac Fibrosis and Remodeling 15
- Cardiac Valve Diseases and Treatments 13
-
- Pulmonary Hypertension Research and Treatments 40
- Co-authors
- Christophe Bauters (46 shared papers)Nicolas Lamblin (66 shared papers)A Millaire (36 shared papers)Eric HACHULLA (25 shared papers)Marc J.C. Humbert (17 shared papers)David Launay (23 shared papers)Gérard Ducloux (20 shared papers)Olivier Sitbon (15 shared papers)
- Journals
- European Heart Journal (20 papers)Archives of cardiovascular diseases (20 papers)American Heart Journal (11 papers)European Journal of Heart Failure (9 papers)International Journal of Cardiology (9 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Pascal de Groote
214 papers receiving 13.6k citations
Pascal de Groote's Hit Papers
Peers
Comparison fields: 5 of 113
- Cardiology and Cardiovascular Medicine 7.8k
- Pulmonary and Respiratory Medicine 3.2k
- Pathology and Forensic Medicine 1.1k
- Cancer Research 424
- Complementary and alternative medicine 285
Countries citing papers authored by Pascal de Groote
This map shows the geographic impact of Pascal de Groote's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal de Groote with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal de Groote more than expected).
Fields of papers citing papers by Pascal de Groote
This network shows the impact of papers produced by Pascal de Groote. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal de Groote. The network helps show where Pascal de Groote may publish in the future.
Co-authors
The 25 scholars most cited alongside Pascal de Groote, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 223 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Hit paper breakdown → | 1999 | 3735 |
| 2 | Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases Hit paper breakdown → | 2016 | 858 |
| 3 | Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study Hit paper breakdown → | 2005 | 591 |
| 4 | Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure Hit paper breakdown → | 2014 | 547 |
| 5 | Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension Hit paper breakdown → | 2017 | 547 |
| 6 | Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure Hit paper breakdown → | 1998 | 541 |
| 7 | 2011 | 313 | |
| 8 | 2011 | 283 | |
| 9 | 2008 | 236 | |
| 10 | 2003 | 172 | |
| 11 | High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. | 2006 | 157 |
| 12 | 2009 | 156 | |
| 13 | 2021 | 153 | |
| 14 | 2021 | 153 | |
| 15 | 2004 | 152 | |
| 16 | Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study Hit paper breakdown → | 2022 | 148 |
| 17 | 2019 | 146 | |
| 18 | 2008 | 137 | |
| 19 | 2012 | 136 | |
| 20 | 2018 | 129 |
About Pascal de Groote
Pascal de Groote is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Complementary and alternative medicine and Rheumatology, having authored 223 papers that have together received 14.3k indexed citations. Recurring topics across this work include Heart Failure Treatment and Management (55 papers), Pulmonary Hypertension Research and Treatments (40 papers), Cardiomyopathy and Myosin Studies (19 papers), Cardiovascular Function and Risk Factors (18 papers), Cardiac Fibrosis and Remodeling (15 papers), Systemic Sclerosis and Related Diseases (14 papers), Cardiac Valve Diseases and Treatments (13 papers) and Cardiovascular and exercise physiology (8 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (7.8k citations), Pulmonary and Respiratory Medicine (3.2k citations), Pathology and Forensic Medicine (1.1k citations), Cancer Research (424 citations) and Complementary and alternative medicine (285 citations). Pascal de Groote has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Christophe Bauters, Nicolas Lamblin, A Millaire, Eric HACHULLA, Marc J.C. Humbert, David Launay, Gérard Ducloux, Olivier Sitbon, Claude Hossein-Foucher and Olivier Nugue. Their work appears in journals such as European Heart Journal, Archives of cardiovascular diseases, American Heart Journal, European Journal of Heart Failure and International Journal of Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.